Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production.
| dc.contributor.author | Geonnotti, Anthony R | |
| dc.contributor.author | Bilska, Miroslawa | |
| dc.contributor.author | Yuan, Xing | |
| dc.contributor.author | Ochsenbauer, Christina | |
| dc.contributor.author | Edmonds, Tara G | |
| dc.contributor.author | Kappes, John C | |
| dc.contributor.author | Liao, Hua-Xin | |
| dc.contributor.author | Haynes, Barton F | |
| dc.contributor.author | Montefiori, David C | |
| dc.coverage.spatial | United States | |
| dc.date.accessioned | 2011-04-15T16:46:19Z | |
| dc.date.issued | 2010-03 | |
| dc.description.abstract | Bacterial lipopolysaccharide (endotoxin) is a frequent contaminant of biological specimens and is also known to be a potent inducer of beta-chemokines and other soluble factors that inhibit HIV-1 infection in vitro. Though lipopolysaccharide (LPS) has been shown to stimulate the production of soluble HIV-1 inhibitors in cultures of monocyte-derived macrophages, the ability of LPS to induce similar inhibitors in other cell types is poorly characterized. Here we show that LPS exhibits potent anti-HIV activity in phytohemagglutinin-stimulated peripheral blood mononuclear cells (PBMCs) but has no detectable anti-HIV-1 activity in TZM-bl cells. The anti-HIV-1 activity of LPS in PBMCs was strongly associated with the production of beta-chemokines from CD14-positive monocytes. Culture supernatants from LPS-stimulated PBMCs exhibited potent anti-HIV-1 activity when added to TZM-bl cells but, in this case, the antiviral activity appeared to be related to IFN-gamma rather than to beta-chemokines. These observations indicate that LPS stimulates PBMCs to produce a complex array of soluble HIV-1 inhibitors, including beta-chemokines and IFN-gamma, that differentially inhibit HIV-1 depending on the target cell type. The results also highlight the need to use endotoxin-free specimens to avoid artifacts when assessing HIV-1-specific neutralizing antibodies in PBMC-based assays. | |
| dc.description.version | Version of Record | |
| dc.identifier | ||
| dc.identifier.eissn | 1931-8405 | |
| dc.identifier.uri | ||
| dc.language | eng | |
| dc.language.iso | en_US | |
| dc.publisher | Mary Ann Liebert Inc | |
| dc.relation.ispartof | AIDS Res Hum Retroviruses | |
| dc.relation.isversionof | 10.1089/aid.2009.0186 | |
| dc.relation.journal | AIDS Research and Human Retroviruses | |
| dc.subject | Antibodies, Monoclonal | |
| dc.subject | Antibodies, Neutralizing | |
| dc.subject | Cell Line, Tumor | |
| dc.subject | Chemokines, CC | |
| dc.subject | Equipment Contamination | |
| dc.subject | Escherichia coli | |
| dc.subject | HIV Infections | |
| dc.subject | HIV-1 | |
| dc.subject | Humans | |
| dc.subject | Interferon-gamma | |
| dc.subject | Leukocytes, Mononuclear | |
| dc.subject | Lipopolysaccharides | |
| dc.subject | Neutralization Tests | |
| dc.subject | Salmonella enterica | |
| dc.title | Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. | |
| dc.type | Journal article | |
| duke.contributor.orcid | Montefiori, David C|0000-0003-0856-6319 | |
| duke.date.pubdate | 2010-3-0 | |
| duke.description.issue | 3 | |
| duke.description.volume | 26 | |
| pubs.author-url | ||
| pubs.begin-page | 279 | |
| pubs.end-page | 291 | |
| pubs.issue | 3 | |
| pubs.organisational-group | Basic Science Departments | |
| pubs.organisational-group | Clinical Science Departments | |
| pubs.organisational-group | Duke | |
| pubs.organisational-group | Duke Cancer Institute | |
| pubs.organisational-group | Duke Human Vaccine Institute | |
| pubs.organisational-group | Global Health Institute | |
| pubs.organisational-group | Immunology | |
| pubs.organisational-group | Institutes and Centers | |
| pubs.organisational-group | Institutes and Provost's Academic Units | |
| pubs.organisational-group | Medicine | |
| pubs.organisational-group | Medicine, Duke Human Vaccine Institute | |
| pubs.organisational-group | School of Medicine | |
| pubs.organisational-group | Surgery | |
| pubs.organisational-group | Surgery, Surgical Sciences Section for AIDS Research & Development | |
| pubs.organisational-group | University Institutes and Centers | |
| pubs.publication-status | Published | |
| pubs.volume | 26 |